New Strategies for Enzyme Replacement Therapy for Lysosomal Storage Diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Enzyme replacement therapy is an established means of treating lysosomal storage diseases. Infused enzymes are normally targeted to the lysosomes of affected cells by interactions with cell-surface receptors that recognize carbohydrate moieties such as mannose and mannose 6-phosphate on the enzymes. Therefore, we have investigated alternative strategies to deliver the lysosomal enzyme β-glucuronidase in the enzyme-deficient mucopolysaccharidosis type VII mouse model. Here we summarize our recent efforts to use nontraditional ways to deliver β-glucuronidase. First, we used a chimeric protein of the insulin-like growth factor II (IGF-II) fused to β-glucuronidase to deliver enzyme via the IGF-II binding site on the bifunctional IGF-II/mannose 6-phosphate receptor. Second, we used the 11-amino-acid human immunodeficiency virus (HIV) Tat domain fused to β-glucuronidase to mediate uptake by absorptive endocytosis. Interaction with heparan sulfate on the cell surface internalizes and delivers the Tat-tagged enzyme to the lysosome via plasma membrane recycling. Third, we created a chimeric β-glucuronidase fused to the Fc portion of human immunoglobulin G (IgG) Fc, which was transported by the neonatal Fc receptor from the maternal circulation across the placenta to sites of storage in fetal tissues. Finally, periodate treatment was used to eliminate interaction with carbohydrate receptors, creating an enzyme with increased plasma half-life, resulting in transport across the blood–brain barrier and clearance of storage in neurons. These strategies for delivering lysosomal enzymes could also be used to target nonlysosomal proteins or enzymes identified for bioremediation of other conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 3×
“17 IgG is delivered from the maternal circulation via interaction with the neonatal form of theFcRn.”
Cited by
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Heparan sulfate proteoglycan as a cell-surface endocytosis receptor
Christianson, H. C., & Belting, M. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.10.004 · Cited by 429
“For example, conjugating β-glucuronidase with the cationic HIV-TAT peptide, or guanidinylated neomycin utilized the high capacity of HSPG-mediated uptake to decrease storage defects in experimental models of lysosomal storage disease (Grubb et al., 2010).”
Organelle targeting: third level of drug targeting
Padh, H., & Sakhrani, N. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s45614 · Cited by 269
Desnick, R. J., & Schuchman, E. H. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163739 · Cited by 269
Katz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Metadata
- Authors
- Grubb, J. H., Vogler, C., & Sly, W. S.
- Venue
- Rejuvenation Research
- Publisher
- SAGE Publications
- Published
- 2010-04
- Volume
- 13
- Issue
- 2-3
- Pages
- 229-236
- ISSN
- 1094-5458 (ISSN-L)
- 1549-1684
- 1557-8577
- OpenAlex
- W1974674708
- Cited by
- 79
- References
- 1
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Strategies for Enzyme Replacement Therapy for Lysosomal Storage Diseases. https://app.cochat.ai/papers/10.1089/rej.2009.0920
- The paper
- Grubb, J. H., Vogler, C., & Sly, W. S. (2010). New Strategies for Enzyme Replacement Therapy for Lysosomal Storage Diseases. Rejuvenation Research. https://doi.org/10.1089/rej.2009.0920
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.